A new study at Moffitt Cancer Center could offer hope to people with melanoma, the deadliest form of skin cancer. Researchers are investigating whether an injectable known as PV-10 can shrink tumors and reduce the spread of cancer. PV-10 is a solution developed from Rose Bengal, a water-soluble dye commonly used to stain damaged cells in the eye. Early clinical trials show PV-10 can boost immune response in melanoma tumors, as well as the blood stream.
"Various injection therapies for melanoma have been examined over the past 40 years, but few have shown the promising results we are seeing with PV-10," said Shari Pilon-Thomas, Ph.D., assistant member of Moffitt's Immunology Program.
In the initial study, researchers injected a single dose of PV-10 into mice with melanoma. The result was a significant reduction in the skin cancer lesions, as well as a sizable reduction in melanoma tumors that had spread to the lungs. The researchers said the dye solution appeared to produce a robust anti-tumor immune response and may be safer than existing immunological agents.
"We are currently in the middle of our first human clinical trial of PV-10 for advanced melanoma patients. In addition to monitoring the response of injected melanoma tumors, we are also measuring the boost in the anti-tumor immune cells of patients after injection," explained Amod A. Sarnaik, M.D., assistant member of Moffitt's Cutaneous Oncology Program.
Explore further: Researchers study 'ACT TIL' approach to treating metastatic melanoma
More information: The initial study appears in PLOS ONE, an open-access, peer-reviewed online journal.
Medical Xpress on facebook
Related Stories
Researchers study 'ACT TIL' approach to treating metastatic melanoma
Oct 17, 2012
Researchers at Moffitt Cancer Center have carried out a clinical trial in which patients with metastatic melanoma were given chemotherapy and an immunotherapy of adoptive cell transfer (ACT) with tumor infiltrating lymphocytes ...
Fast-acting virus targets melanoma in mice
Jun 17, 2013
(Medical Xpress)—Yale researchers eradicated most melanoma tumors by exposing them to a fast-acting virus, they report in the June 15 edition of the Journal of Virology.
Enhanced treatment, surveillance needed for certain melanoma patients to prevent secondary cancers
Aug 14, 2013
Moffitt Cancer Center researchers suggest secondary cancers seen in melanoma patients who are being treated for a BRAF gene mutation may require new strategies, such as enhanced surveillance and combining BRAF-inhibitor therapy ...
New screening approach identifies small proteins unique to melanoma cells, researcher says
Jun 25, 2013
Jamie K. Teer, Ph.D., assistant member of the Cancer Biology and Evolution Program at Moffitt Cancer Center, and colleagues have developed a new streamlined method to rapidly identify the genetic changes in small protein ...
Clinical trial assesses anti-melanoma vaccine's ability to induce an anti-cancer immune response
Jul 11, 2013
Cancer vaccines prime the immune system to attack cancer cells, decreasing tumor progression. IL-12p70, a molecule produced by certain types of immune cells, has been shown to reduce tumor progression, but delivering it as ...
Recommended for you
Drug used for blood cancers may stop spread of breast cancer cells
8 hours ago
A drug used to treat blood cancers may also stop the spread of invasive breast cancer, researchers at Mayo Clinic in Florida have discovered. Their study, published online in Breast Cancer Research, found that in the lab an ...
The stress and cancer link: 'Master switch' stress gene enables cancer's spread
11 hours ago
In an unexpected finding, scientists have linked the activation of a stress gene in immune-system cells to the spread of breast cancer to other parts of the body.
Foreign-born hispanics have survival advantage in NSCLC
13 hours ago
(HealthDay)—Compared with non-Hispanic whites (NHWs) and U.S.-born Hispanics, foreign-born Hispanics with non-small-cell lung cancer (NSCLC) have a reduced risk of disease-specific mortality, according ...
Study helps explain increased melanoma risk in individuals with red hair
15 hours ago
A person's skin pigment, which determines hair color and skin tone, is influenced by the melanocortin-1 (MC1R) gene receptor. For the population's one to two percent of redheads, a mutation in MC1R accounts for their red ...
Targeted cancer treatment: Cause of skin infections identified
18 hours ago
Targeted, successful cancer treatments are very often accompanied by unpleasant side effects. Especially in anti-EGFR treatments the skin is often so badly affected by inflammations that patients consider ...
Scientists pinpoint a new molecular mechanism tied to pancreatic cancer
20 hours ago
(Medical Xpress)—New research led by scientists at The University of Texas Health Science Center at Houston (UTHealth) and Baylor College of Medicine could aid efforts to diagnose and treat one of the most lethal and hard-to-treat ...
User comments
© Medical Xpress 2011-2013, Phys.org network
A new study at Moffitt Cancer Center could offer hope to people with melanoma, the deadliest form of skin cancer. Researchers are investigating whether an injectable known as PV-10 can shrink tumors and reduce the spread of cancer. PV-10 is a solution developed from Rose Bengal, a water-soluble dye commonly used to stain damaged cells in the eye. Early clinical trials show PV-10 can boost immune response in melanoma tumors, as well as the blood stream.
"Various injection therapies for melanoma have been examined over the past 40 years, but few have shown the promising results we are seeing with PV-10," said Shari Pilon-Thomas, Ph.D., assistant member of Moffitt's Immunology Program.
In the initial study, researchers injected a single dose of PV-10 into mice with melanoma. The result was a significant reduction in the skin cancer lesions, as well as a sizable reduction in melanoma tumors that had spread to the lungs. The researchers said the dye solution appeared to produce a robust anti-tumor immune response and may be safer than existing immunological agents.
"We are currently in the middle of our first human clinical trial of PV-10 for advanced melanoma patients. In addition to monitoring the response of injected melanoma tumors, we are also measuring the boost in the anti-tumor immune cells of patients after injection," explained Amod A. Sarnaik, M.D., assistant member of Moffitt's Cutaneous Oncology Program.
Explore further: Researchers study 'ACT TIL' approach to treating metastatic melanoma
More information: The initial study appears in PLOS ONE, an open-access, peer-reviewed online journal.
Medical Xpress on facebook
Related Stories
Researchers study 'ACT TIL' approach to treating metastatic melanoma
Oct 17, 2012
Researchers at Moffitt Cancer Center have carried out a clinical trial in which patients with metastatic melanoma were given chemotherapy and an immunotherapy of adoptive cell transfer (ACT) with tumor infiltrating lymphocytes ...
Fast-acting virus targets melanoma in mice
Jun 17, 2013
(Medical Xpress)—Yale researchers eradicated most melanoma tumors by exposing them to a fast-acting virus, they report in the June 15 edition of the Journal of Virology.
Enhanced treatment, surveillance needed for certain melanoma patients to prevent secondary cancers
Aug 14, 2013
Moffitt Cancer Center researchers suggest secondary cancers seen in melanoma patients who are being treated for a BRAF gene mutation may require new strategies, such as enhanced surveillance and combining BRAF-inhibitor therapy ...
New screening approach identifies small proteins unique to melanoma cells, researcher says
Jun 25, 2013
Jamie K. Teer, Ph.D., assistant member of the Cancer Biology and Evolution Program at Moffitt Cancer Center, and colleagues have developed a new streamlined method to rapidly identify the genetic changes in small protein ...
Clinical trial assesses anti-melanoma vaccine's ability to induce an anti-cancer immune response
Jul 11, 2013
Cancer vaccines prime the immune system to attack cancer cells, decreasing tumor progression. IL-12p70, a molecule produced by certain types of immune cells, has been shown to reduce tumor progression, but delivering it as ...
Recommended for you
Drug used for blood cancers may stop spread of breast cancer cells
8 hours ago
A drug used to treat blood cancers may also stop the spread of invasive breast cancer, researchers at Mayo Clinic in Florida have discovered. Their study, published online in Breast Cancer Research, found that in the lab an ...
The stress and cancer link: 'Master switch' stress gene enables cancer's spread
11 hours ago
In an unexpected finding, scientists have linked the activation of a stress gene in immune-system cells to the spread of breast cancer to other parts of the body.
Foreign-born hispanics have survival advantage in NSCLC
13 hours ago
(HealthDay)—Compared with non-Hispanic whites (NHWs) and U.S.-born Hispanics, foreign-born Hispanics with non-small-cell lung cancer (NSCLC) have a reduced risk of disease-specific mortality, according ...
Study helps explain increased melanoma risk in individuals with red hair
15 hours ago
A person's skin pigment, which determines hair color and skin tone, is influenced by the melanocortin-1 (MC1R) gene receptor. For the population's one to two percent of redheads, a mutation in MC1R accounts for their red ...
Targeted cancer treatment: Cause of skin infections identified
18 hours ago
Targeted, successful cancer treatments are very often accompanied by unpleasant side effects. Especially in anti-EGFR treatments the skin is often so badly affected by inflammations that patients consider ...
Scientists pinpoint a new molecular mechanism tied to pancreatic cancer
20 hours ago
(Medical Xpress)—New research led by scientists at The University of Texas Health Science Center at Houston (UTHealth) and Baylor College of Medicine could aid efforts to diagnose and treat one of the most lethal and hard-to-treat ...
User comments
© Medical Xpress 2011-2013, Phys.org network
0 comments:
Post a Comment